维力医疗公告称，近日公司欧盟医疗器械法规（MDR）认证证书新增多个产品的欧盟MDR认证。包括 Ⅰ类灭菌的导尿管护理包等产品、Ⅱa类的微网雾化器（耗材）等产品、Ⅱb类的导尿包等产品，发证机 构均为TÜVSÜD Product Service GmbH，证书签批时间多为2026/2/3，到期时间在2028年。获认证表明 产品符合欧盟法规要求，具备欧盟市场准入条件，利于产品推广销售，但无法预测对未来业绩的具体影 响。 ...

Core Viewpoint - The "Shengong-Hua Tuo" brain-controlled acupuncture and neuro-rehabilitation equipment platform has been launched in Tianjin, marking a significant advancement in integrating traditional Chinese medicine with cutting-edge brain-computer interface technology [1][2]. Group 1: Technology and Innovation - The platform targets patients with neurological disorders such as stroke-induced paralysis, utilizing a combination of brain-computer interface (BCI) and smart wearable acupuncture technology [1]. - Three core technologies have been developed: "Active Acupuncture," "Quantitative Acupuncture," and "Integrated Acupuncture," addressing key challenges in traditional acupuncture practices [2]. - The "Active Acupuncture" technology enhances patient engagement by allowing the brain to actively participate in the acupuncture process [2]. - "Quantitative Acupuncture" provides real-time evaluation of acupuncture effects, optimizing the treatment feedback loop [2]. - "Integrated Acupuncture" creates a sensory-motor coupling rehabilitation system by accurately detecting brain activity in sensory and motor areas [2]. Group 2: Research and Development - The research team has been focused on modernizing traditional Chinese medicine techniques and integrating them with advanced technologies like brain-computer interfaces [3]. - Previous projects include the development of a portable transcutaneous electrical stimulation device, which has been used in space missions to ensure astronaut health [3]. - Future plans involve the continued development of brain-controlled acupuncture and massage equipment, contributing to the evolution of "smart traditional Chinese medicine" [3].

Group 1 - The article discusses the performance and characteristics of various ETFs tracking the STAR Market indices, highlighting their focus on high-tech sectors such as semiconductors, medical devices, and software development [2][3] - The STAR 50 ETF tracks the STAR 50 Index, which consists of 50 stocks with large market capitalization and good liquidity, with over 65% of its composition in semiconductors and nearly 80% in hard technology sectors [2] - The STAR 100 ETF focuses on 100 medium-cap stocks, with over 75% of its composition in electronics, power equipment, and pharmaceutical industries [2] - The STAR 200 ETF targets 200 small-cap stocks, emphasizing growth potential, with significant representation from electronics, biomedical, and machinery sectors [2] - The STAR Composite Index ETF covers all market segments and focuses on core industries such as artificial intelligence, semiconductors, and innovative pharmaceuticals, encompassing all 17 primary industries listed on the STAR Market [3] - The STAR Growth ETF includes 50 stocks with high growth rates in revenue and net profit, with over 65% of its composition in the electronics and communications sectors [3] Group 2 - As of the midday close on February 4, 2026, the STAR 50 Index showed a decline, while the STAR 100 Index had a rolling P/E ratio of 213.8 times, and the STAR 200 Index had a rolling P/E ratio of 167.4 times [2] - The STAR Composite Index had a rolling P/E ratio of 223.3 times, and the STAR Growth Index had a rolling P/E ratio of 193.2 times, indicating varying levels of valuation across these indices [3] - The article notes that the STAR Market indices have been established at different times, with the STAR 50 Index launched on July 23, 2020, the STAR 100 Index on August 7, 2023, the STAR 200 Index on August 20, 2024, and the STAR Composite Index on November 4, 2022 [3]

观点网讯：近日，脑机交互与人机共融海河实验室宣布，由周鹏智慧中医团队牵头，联合天津中医药大 学第一附属医院、滨海新区中医医院、天津中医药大学及天中依脉公司共同研发的全国首个脑控针灸融 合神经康复装备平台"神工-华佗"正式落地。 该平台集成"脑机接口+智能穿戴式针灸"技术，可将患者脑电信号实时转化为精准穴位电刺激参数，实 现个体化康复干预。项目曾获国家载人航天实验专项支持，其前身"便携式经皮穴位电刺激装置"已随多 艘神舟载人飞船完成太空验证，为中医智能化装备在天基环境下的应用奠定基础。 免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 ...

Core Viewpoint - Medtronic plans to exercise its acquisition option for CathWorks, a private company specializing in coronary physiological assessment technology, with a total consideration of up to $585 million (approximately 4.1 billion RMB) [2] Group 1: Acquisition Details - The acquisition is expected to be completed before the end of Medtronic's fiscal year 2026, pending review by the U.S. Federal Trade Commission (FTC) [2] - This move follows a strategic partnership established in 2022 between Medtronic and CathWorks to promote the FFRangio system in the U.S., Europe, and Japan [3] Group 2: Technology and Product Path - The acquisition signifies Medtronic's commitment to the coronary physiological assessment technology route [4] - CathWorks' FFRangio system generates FFR value distribution across the entire coronary tree based on standard coronary angiography images, utilizing AI and computational fluid dynamics without the need for pressure wires or drug stimulation [9] Group 3: Decision Support Capabilities - FFRangio has evolved beyond a diagnostic tool to become a real-time decision support layer in interventional procedures, aligning with Medtronic's focus on data-driven and integrated processes in interventional fields [11][13] - The technology provides real-time data to support personalized treatment strategies and has the potential to reshape the workflow in catheterization labs [16] Group 4: Strategic Implications - The acquisition indicates a shift in the competitive focus of coronary interventions from "device itself" to "decision efficiency" [17] - The integration of imaging, AI, and physiological assessment is moving towards a unified platform, enhancing the value of tools embedded in the complete interventional process [17] - Large platform companies prefer to accelerate the acquisition of key capabilities through mergers rather than internal development [18] Group 5: Financial Impact - The acquisition is expected to have a negligible impact on Medtronic's GAAP and adjusted EPS for fiscal year 2027, with potential neutral to positive contributions in the medium to long term [19] - Prior to the completion of the transaction, Medtronic and CathWorks will continue to operate independently, allowing for further integration of products, channels, and teams [20] Group 6: Industry Trends - The acquisition reflects a trend in mature interventional fields where innovation is shifting towards reducing hesitation and increasing certainty in decision-making [21] - Companies that can simplify complex judgments and seamlessly integrate into physicians' daily workflows are likely to gain a competitive advantage in the next phase [22] - CathWorks provides Medtronic with a ready-made solution to address these challenges [23]

Core Viewpoint - The article highlights the launch of China's first brain-controlled acupuncture and neuro-rehabilitation equipment platform, "Shengong-Hua Tuo," developed by a collaborative team led by the Brain-Computer Interaction and Human-Machine Integration Haihe Laboratory [1]. Group 1 - The innovative technology combines "brain-computer interface + smart wearable acupuncture," supported by multiple preliminary projects, including the national manned spaceflight experimental project [2]. - The research team has focused on the modernization of traditional Chinese medicine (TCM) technologies and the integration of cutting-edge technologies like brain-computer interfaces for several years [2]. - A previous collaboration between Tianjin University and Tianjin University of Traditional Chinese Medicine resulted in the development of a "portable transcutaneous acupoint electrical stimulation device (space acupuncture)," which has been tested in space aboard several Shenzhou series manned spacecraft, marking a pioneering application of TCM smart acupuncture equipment in space [3].

公司业绩保持快速增长，2025年营收体量突破10亿 近期，公司发布2025年业绩预告，预期2025年全年营收超10.5亿元，同比增长约34.6%；全年净利润超2.4亿元，同 比增长约139.4%。 2025年公司海外市场渗透率持续提升，海外市场营收同比增长超过100%。 战略收购德国Optimed公司，海外市场拓展全面提速 2026年1月，公司宣布战略收购德国Optimed公司，进一步拓展在欧洲及全球市场的布局，加快创新产品在国际市 场的推广与落地；同时依托中、德两大生产基地之间的协同效应，持续提升全球化运营与交付能力。 归创通桥：国产神经介入+外周介入龙头企业，积极布局海外市场 公司业绩保持快速增长，2025年营收体量突破10亿 近期，公司发布2025年业绩预告，预期2025年全年营收超10.5亿元，同比增长约34.6%；全年净利润超2.4亿元，同 比增长约139.4%。 2025年公司海外市场渗透率持续提升，海外市场营收同比增长超过100%。 战略收购德国Optimed公司，海外市 归创通桥：国产神经介入+外周介入龙头企业，积极布局海外市场 看好公司长期发展 预计2026、2027年公司营收（不考虑外延并 ...

Group 1 - The core viewpoint of the article is that Blue Sail Medical has reported a positive turnaround in the gross margin of its glove products starting from the fourth quarter of 2025 [1] - As of January 2026, glove prices have shown a steady recovery [1] - The company is enhancing its cost competitiveness through various initiatives, including the integration of nitrile glove production capacity with Thai industrial investors, the acquisition of Hongda Thermal Power to address energy supply shortages, and the establishment of a self-owned power plant at its Weifang factory [1]

Core Viewpoint - The company, Bluestar Medical, announced significant advancements in its product development, specifically the SoniCracker™-CL catheter and the Lithonic™ system, which are expected to enhance its market position in the medical device industry [1] Group 1: Product Development - The SoniCracker™-CL, a disposable intravascular shockwave catheter, is set to receive the medical device registration certificate from NMPA in 2024 [1] - The Lithonic™ intravascular shockwave therapy system is anticipated to obtain CE certification in January 2026, enabling the company to initiate overseas sales shortly thereafter [1] - The company expects rapid market penetration and sales growth for the Lithonic™ system following its certification [1]

Core Viewpoint - Blue Sail Medical aims to achieve profitability in its cardiovascular division by 2025, indicating a significant turnaround from previous losses [1] Financial Performance - The company reported a net profit exceeding 100 million yuan in operational terms after excluding the negative impact of over 100 million yuan from the fair value changes of its investment in Tongxin Medical [1] - This marks a substantial improvement from a loss of approximately 140 million yuan in 2024 to a profit of over 100 million yuan in 2025 [1]